Developing biotech products is scientifically demanding, capital-intensive time-consuming, and involves significant commercial risk. Securing the benefits of biotechnology requires a policy environment that enables scientists, businesses, investors, and regulators to work together to discover, develop, and bring to market innovative biotech products.
Internationally regarded biotech policies facilitate research cooperation among private, non-profit, and governmental organizations; protect intellectual property rights to attract the private investment necessary to support biotech innovations; provide a transparent and predictable regulatory approval process that is science-based and internationally recognized; and maintain transparent non-discriminatory, competitive, and commercially viable markets for biotech products. These principles are described as the critical components of a national industrial policy in BIO’s newly published Policy Principles to Promote Biotechnology.
Countries all over the world are recognizing the importance of biotechnology to their economies, the health and wellbeing of their citizens, their food supply, and their ability to generate clean energy. Nearly every major country has adopted programs to generate a homegrown biotechnology sector and the well-paying jobs it supports.
The realization of the benefits of an innovation economy has spread beyond the U.S. and Europe to emerging economies as well. Last year, BIO’s Global Biotechnology Forum focused on the “BRICs and Beyond,” exploring how governments of the major emerging BRIC countries are developing the frameworks for the growth of a domestic biotech sector.
This year’s Global Biotechnology Forum seeks to continue this conversation. The Global Biotechnology Forum: Promoting Best Practices in Biotech Policy focuses on the specific policy principles that governments of major emerging markets are putting in place to create a domestic marketplace based on globally recognized best practices.
In today’s globalized and interconnected world where opportunities are plenty and dollars are finite, there is competition to secure the resources that can help a biotech sector grow. In the game of global commerce, life sciences investment will seek out those destinations that provide stable, market-based, and collaborative opportunities. BIO’s 2013 Global Biotechnology Forum seeks to draw out those themes by analyzing the best policy practices that countries have used to promote their biotech sectors.
The ministerial-level panelists are some of the leading senior government policy and decision makers in devising and implementing an innovative biotech platform. Topics to be covered will include:
- Concrete measures to promote domestic and foreign investment in biotechnology;
- Funding for university research facilities, collaborations, and commercialization to advance the domestic biotechnology industry;
- Patent and IPR laws and protections to encourage innovation and investment;
- Science-based and transparent preclinical, clinical, and post-marketing regulations and trial rules;
- Market access and reimbursement rules to promote an environment that incentivizes risk-taking and patient care;
- International regulatory cooperation and harmonization.
- Mr. Daniel M. Price, Managing Director, Rock Creek Global Advisors LLC
- The Honourable Mehmet Müezzinoglu, Minister of Health, Republic of Turkey
- Professor Emeritus Dato’ Dr Zakri Abdul Hamid, Science Advisor to the Prime Minister, Malaysia
- Ms. Ilona Antoniszyn-Klik, Undersecretary of State, Ministry of Economy, Poland
- Mr. Tim Hubbard, Special Advisor on Genomics, NHS England
Session ID: 2022